Sodium heparin

Sodium heparin
Name	Sodium heparin
Other names	Heparin sodium
Formula	variable polysaccharide
Cas number	9041-08-1
Mol weight	heterogeneous

Sodium heparin is a highly sulfated glycosaminoglycan used as an anticoagulant in clinical medicine and laboratory practice. It is derived from animal tissues and supplied as a sodium salt for intravenous and subcutaneous administration and as anticoagulant-coated blood collection devices. Sodium heparin has played a role in modern medicine alongside developments at institutions such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and Karolinska Institutet.

Chemistry and Structure

Sodium heparin is a heterogeneous, linear polysaccharide composed of repeating disaccharide units of uronic acids and glucosamine residues, often bearing N-sulfate and O-sulfate groups; its structural elucidation involved researchers associated with University of Cambridge, Harvard University, Stanford University, University of Oxford, and Max Planck Society. The average molecular weight varies widely, with preparations characterized by analytical techniques developed at facilities like National Institutes of Health, European Molecular Biology Laboratory, Scripps Research, and Cold Spring Harbor Laboratory. Chemical modification and low–molecular-weight heparin production trace methodological roots to work at Eli Lilly and Company, Bayer, GlaxoSmithKline, and Sanofi. Structural heterogeneity affects interactions with proteins such as antithrombin III, whose three-dimensional structure has been studied by groups at Weizmann Institute of Science and European Synchrotron Radiation Facility.

Medical and Clinical Uses

Clinically, sodium heparin is used for prophylaxis and treatment of venous thromboembolism, management of acute coronary syndromes, and maintenance of vascular catheter patency—applications developed within clinical trials and practice settings at Cleveland Clinic, Royal Brompton Hospital, Mount Sinai Hospital, Columbia University Irving Medical Center, and Guy's and St Thomas' NHS Foundation Trust. In laboratory medicine, it is used as an anticoagulant for blood gas analysis and some hematology tests; these practices are standardized by organizations such as the World Health Organization, Centers for Disease Control and Prevention, Food and Drug Administration, and European Medicines Agency. Sodium heparin is also employed during cardiopulmonary bypass and hemodialysis in centers like Boston Children's Hospital, University College London Hospitals, and Karolinska University Hospital.

Pharmacology and Mechanism of Action

Sodium heparin exerts anticoagulant effects primarily by binding to antithrombin III, accelerating inactivation of thrombin (factor IIa) and factor Xa; foundational biochemical studies were contributed by investigators at Rockefeller University, Yale University, University of Pennsylvania, and Imperial College London. The pharmacodynamic profile is influenced by plasma proteins and endothelial interactions characterized in studies from University of California, San Francisco, McGill University, and Technion – Israel Institute of Technology. Heparin’s pleiotropic effects, including modulation of complement and growth factors, have been explored in collaborations involving Johns Hopkins University, Massachusetts Institute of Technology, Duke University, and University of Toronto. Heparin clearance pathways involve the reticuloendothelial system and renal filtration, topics studied at Karolinska Institutet, National Institutes of Health, and University of Michigan.

Dosage, Administration, and Monitoring

Dosage regimens for sodium heparin vary by indication and institutional protocols from hospitals such as Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, and Mount Sinai Hospital; common approaches include intravenous bolus followed by infusion or weight-based subcutaneous injections. Monitoring frequently employs the activated partial thromboplastin time (aPTT) with standards developed in laboratories at St Thomas' Hospital, Royal Infirmary of Edinburgh, University Hospital Zurich, and Guy's and St Thomas' NHS Foundation Trust; anti–factor Xa assays are used in specialized centers like Johns Hopkins Hospital, Vanderbilt University Medical Center, and University of California, San Diego. Perioperative and dialysis dosing protocols have been refined in cardiac centers such as Cleveland Clinic, Papworth Hospital, Royal Papworth Hospital, and Texas Heart Institute.

Adverse Effects and Contraindications

Major adverse effects include bleeding complications, heparin-induced thrombocytopenia (HIT), and osteoporosis with long-term use; recognition and management guidelines are provided by professional bodies like the American College of Cardiology, American Heart Association, European Society of Cardiology, and British Society for Haematology. HIT pathogenesis and diagnostic criteria were elucidated through research at University of Toronto, University of Oxford, University of California, San Francisco, and University of North Carolina at Chapel Hill. Contraindications commonly cited by institutions such as Mayo Clinic, NIH Clinical Center, Royal College of Physicians, and Australian Therapeutic Goods Administration include active bleeding and severe thrombocytopenia; reversal strategies often reference protamine sulfate protocols from emergency departments at Johns Hopkins Hospital, Massachusetts General Hospital, and Mount Sinai Hospital.

Production, Formulation, and Storage

Commercial sodium heparin production historically sources porcine intestinal mucosa and bovine lung tissue, with supply-chain oversight involving manufacturers like Pfizer, TEVA Pharmaceutical Industries, Johnson & Johnson, and Fresenius Kabi; regulatory scrutiny intensified after contamination events investigated by US Food and Drug Administration and European Medicines Agency. Formulations include aqueous solutions for injection and heparin-coated medical devices produced for use in clinics such as Royal Free Hospital, Charité – Universitätsmedizin Berlin, Toronto General Hospital, and Cedars-Sinai Medical Center. Storage recommendations—temperature control, protection from light, and shelf-life monitoring—are standardized in pharmacopeial references maintained by United States Pharmacopeia, European Pharmacopoeia, and British Pharmacopoeia.

Category:Anticoagulants